ClinicalTrials.gg
CompletedNCT04417894Updated Dec 22, 2023Results posted

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)

A Phase 3 interventional study of dupilumab and Placebo in Moderate to Severe Atopic Hand and Foot Dermatitis, sponsored by Regeneron Pharmaceuticals. Completed at 48 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2023-12-22.

Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
133
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

The primary objective of the study is to assess the efficacy of dupilumab on skin lesions in patients with atopic hand and foot dermatitis.

The secondary objectives of the study are:

  • To assess the efficacy of dupilumab on various other domains (pruritus, pain, sleep loss, health related QoL, work life impairment) in patients with atopic hand and foot dermatitis
  • To evaluate the safety and tolerability of dupilumab administered to patients with atopic hand and foot dermatitis
  • To evaluate systemic exposure and immunogenicity of dupilumab in patients with atopic hand and foot dermatitis
02

Conditions studied

  • Moderate to Severe Atopic Hand and Foot Dermatitis
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patients with involvement of at least 2 anatomical areas at screening and baseline
  • Patients need to have an IGA hand and foot score of 3 or 4 (moderate-to-severe disease) at screening and baseline
  • Patients with documented recent history (within 6 months before the screening visit) of inadequate response of atopic hand and foot dermatitis to topical medication(s)
  • Patients meet the diagnosis criteria for atopic dermatitis (AD)
  • Provide /assent signed by study patient or legally acceptable representative
  • Patients need to have been compliant with the skin protection measures through the entire duration of the screening period

Key Exclusion Criteria:

  • Treatment with dupilumab in the past
  • Patients with a positive patch test reaction that are deemed to be as the current cause of the hand and foot dermatitis
  • Patients with documented exposure to irritants believed to be a predominant cause of the current hand and foot dermatitis
  • Treatment with systemic or non-steroidal drugs within 4 weeks prior to baseline
  • Known history of // infection
  • Pregnant or breastfeeding women or planning to become pregnant or breastfeed during the patient's participation in this study
  • Women of (WOCBP) who are unwilling to practice highly effective prior to the initial dose/start of the first treatment and during the study

NOTE: Other protocol defined inclusion / exclusion criteria apply

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
133 participants (actual)

Study arms

  • Experimental
    dupilumab

    Administered subcutaneously (SC) once every 2 weeks (Q2W), following a loading dose on Day 1

    Drug: dupilumab

  • Experimental
    Matching Placebo

    Administered SC Q2W, following a loading dose on Day 1

    Drug: Placebo

Interventions

  • Solution for subcutaneous (SC) injection administration

    Also known as: DUPIXENT®, REGN668, SAR231893

  • DrugPlacebo

    Solution for SC injection administration

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16

    IGA is an assessment scale used to determine severity of hand and foot AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Higher score is indicative of more severe disease.

    Time frame: At week 16

Secondary outcomes

  1. Percentage of Participants With Improvement (Reduction) of Weekly Average of Daily Hand and Foot Peak Pruritus Numerical Rating Scale (NRS) of ≥4 Points From Baseline to Week 16

    Pruritus NRS is an assessment tool that is used to report the intensity of a patient's pruritus (itch), both maximum and average intensity, during a 24-hour recall period; maximum itch intensity on a scale of 0 - 10 (0 = no itch; 10 = worst itch imaginable).

    Time frame: Baseline to week 16

  2. Percentage of Participants With Improvement (Reduction) of Weekly Average of Daily Hand and Foot Peak Pruritus NRS ≥3 From Baseline to Week 16

    Pruritus NRS is an assessment tool that is used to report the intensity of a patient's pruritus (itch), both maximum and average intensity, during a 24-hour recall period; maximum itch intensity on a scale of 0 - 10 (0 = no itch; 10 = worst itch imaginable).

    Time frame: Baseline to week 16

  3. Percent Change From Baseline to Week 16 in Weekly Average of Daily Hand and Foot Peak Pruritus NRS

    Pruritus NRS is an assessment tool that is used to report the intensity of a patient's pruritus (itch), both maximum and average intensity, during a 24-hour recall period; maximum itch intensity on a scale of 0 - 10 (0 = no itch; 10 = worst itch imaginable).

    Time frame: Baseline to week 16

  4. Percent Change in Modified Total Lesion Sign Score (mTLSS) for Hand/Foot Lesions From Baseline to Week 16

    mTLSS combines an evaluation of hand and foot eczema lesions severity; scores are summed, extending from a base estimation of 0 (no signs or symptoms) to the most extreme of 18 (more serious disease).

    Time frame: Baseline to Week 16

  5. Change From Baseline to Week 16 in Weekly Average of Daily Hand and Foot Peak Pain NRS

    Pain NRS Scale is an assessment tool used to report the intensity of a participant's pain. Participants will select the number between 0 and 10 that fits best to their worst pain intensity over the past 24 hours (0 = no pain and 10 = the worst pain possible).

    Time frame: Baseline to week 16

  6. Mean Change From Baseline to Week 16 in Weekly Average of Daily Sleep NRS

    Sleep NRS is an 11-point scale (0 to 10) in which 0 indicates worst possible sleep while 10 indicates best possible sleep.

    Time frame: Baseline to week 16

  7. Change From Baseline to Week 16 in Percent Surface Area of Hand and Foot Involvement With Atopic Dermatitis (AD)

    Time frame: Baseline to week 16

  8. Percent Change From Baseline to Week 4 in Weekly Average of Daily Hand and Foot Peak Pruritus NRS

    Pruritus NRS is an assessment tool that is used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period; maximum itch intensity on a scale of 0 - 10 (0 = no itch; 10 = worst itch imaginable).

    Time frame: Baseline to week 4

  9. Percentage of Participants With Improvement (Reduction) of Weekly Average of Daily Hand and Foot Peak Pruritus NRS ≥4 From Baseline to Week 4

    Pruritus NRS is an assessment tool that is used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period; maximum itch intensity on a scale of 0 - 10 (0 = no itch; 10 = worst itch imaginable).

    Time frame: Baseline to week 4

  10. Percent Change From Baseline to Week 16 in Hand Eczema Severity Index (HECSI) Score in Participants With Hand Dermatitis

    For participants with hand dermatitis HECSI is an instrument used in clinical trials to rate the severity of 6 clinical signs of hand eczema and the extent of the lesions on each of 5 hand areas by use of standard scales. The total HECSI score is based on a 4-point severity scale ranging from 0 (none/absent) to 3 (severe) and a 5-point scale rating the affected area(s) ranging from 0 (0% affected area) to 4 (76% to 100% affected area). The range for the combined HECSI score is from 0 to 360 (5x6x3x4).

    Time frame: Baseline to week 16

  11. Percentage of Participants With HECSI-75 at Week 16

    HECSI-75 is defined as HECSI score has ≥75% improvement from baseline for participants with hand dermatitis.

    Time frame: At week 16

  12. Percentage of Participants With HECSI-50 at Week 16

    HECSI-50 is defined as HECSI score has ≥50% improvement from baseline, for participants with hand dermatitis.

    Time frame: At week 16

  13. Percentage of Participants With HECSI-90 at Week 16

    HECSI-90 is defined as HECSI score has ≥90% improvement from baseline for participants with hand dermatitis.

    Time frame: At week 16

  14. Change From Baseline to Week 16 in Quality of Life in Hand Eczema Questionnaire (QOLHEQ)

    For participants with hand dermatitis, QOLHEQ is an instrument to assess disease specific Health Related Quality of Life (HRQOL) in those suffering from hand eczema. QOLHEQ overall scoring ranges as follows: 0 (best score) to 117 (worst score).

    Time frame: Baseline to week 16

  15. Mean Change From Baseline to Week 16 in Work Productivity and Impairment (WPAI) and Classroom Impairment Questionnaire (CIQ)

    WPAI + CIQ is a self-administered instrument used to capture the impairment to work productivity/classroom impairment and activity due to atopic hand and foot dermatitis. The WPAI+CIQ yields 4 types of scores: absenteeism, presenteeism, work/classroom productivity loss and activity impairment. All scores range from 0 to 100% with 100% indicating total work/classroom productivity impairment and 0 no impairment at all.

    Time frame: Baseline to week 16

  16. Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Through Week 16

    Time frame: Through week 16

  17. Trough Concentration of Functional Dupilumab in Serum at Various Time Points

    Time frame: Up to week 28

  18. Number of Participants With Treatment-Emergent (TE) Anti-Drug Antibody (ADA)

    Time frame: Up to week 28

  19. Number of Participants With Treatment-Emergent ADA by Maximum Titer Category

    Time frame: Up to Week 28

07

Results

Posted Dec 22, 2023

Participant flow

Participant flow — Overall Study
MilestoneMatching PlaceboDupilumab Q2W
Started6667
Completed5360
Not completed137
Withdrew: Lost to follow-up30
Withdrew: Withdrawal by subject76
Withdrew: Lack of efficacy31

Outcome measures

PrimaryPercentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16

IGA is an assessment scale used to determine severity of hand and foot AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Higher score is indicative of more severe disease.

Time frame:
At week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16
Percentage of participantsMatching PlaceboDupilumab Q2W
Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 1616.740.3
Statistical analysis
  • Matching Placebo vs Dupilumab Q2W · Cochran-Mantel-Haenszel · p = =0.0030
SecondaryPercentage of Participants With Improvement (Reduction) of Weekly Average of Daily Hand and Foot Peak Pruritus Numerical Rating Scale (NRS) of ≥4 Points From Baseline to Week 16

Pruritus NRS is an assessment tool that is used to report the intensity of a patient's pruritus (itch), both maximum and average intensity, during a 24-hour recall period; maximum itch intensity on a scale of 0 - 10 (0 = no itch; 10 = worst itch imaginable).

Time frame:
Baseline to week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Improvement (Reduction) of Weekly Average of Daily Hand and Foot Peak Pruritus Numerical Rating Scale (NRS) of ≥4 Points From Baseline to Week 16
Percentage of participantsMatching PlaceboDupilumab Q2W
Percentage of Participants With Improvement (Reduction) of Weekly Average of Daily Hand and Foot Peak Pruritus Numerical Rating Scale (NRS) of ≥4 Points From Baseline to Week 1613.652.2
Statistical analysis
  • Matching Placebo vs Dupilumab Q2W · Mantel Haenszel · p = <0.0001 · Difference: 38.6 · 95% CI 24.06 to 53.15
SecondaryPercentage of Participants With Improvement (Reduction) of Weekly Average of Daily Hand and Foot Peak Pruritus NRS ≥3 From Baseline to Week 16

Pruritus NRS is an assessment tool that is used to report the intensity of a patient's pruritus (itch), both maximum and average intensity, during a 24-hour recall period; maximum itch intensity on a scale of 0 - 10 (0 = no itch; 10 = worst itch imaginable).

Time frame:
Baseline to week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Improvement (Reduction) of Weekly Average of Daily Hand and Foot Peak Pruritus NRS ≥3 From Baseline to Week 16
Percentage of participantsMatching PlaceboDupilumab Q2W
Percentage of Participants With Improvement (Reduction) of Weekly Average of Daily Hand and Foot Peak Pruritus NRS ≥3 From Baseline to Week 1616.761.2
SecondaryPercent Change From Baseline to Week 16 in Weekly Average of Daily Hand and Foot Peak Pruritus NRS

Pruritus NRS is an assessment tool that is used to report the intensity of a patient's pruritus (itch), both maximum and average intensity, during a 24-hour recall period; maximum itch intensity on a scale of 0 - 10 (0 = no itch; 10 = worst itch imaginable).

Time frame:
Baseline to week 16
Reported as:
Least squares mean · Percentage of change
Percent Change From Baseline to Week 16 in Weekly Average of Daily Hand and Foot Peak Pruritus NRS
Percentage of changeMatching PlaceboDupilumab Q2W
Percent Change From Baseline to Week 16 in Weekly Average of Daily Hand and Foot Peak Pruritus NRS-26.2 (-38.0 to -14.4)-62.9 (-74.6 to -51.3)
SecondaryPercent Change in Modified Total Lesion Sign Score (mTLSS) for Hand/Foot Lesions From Baseline to Week 16

mTLSS combines an evaluation of hand and foot eczema lesions severity; scores are summed, extending from a base estimation of 0 (no signs or symptoms) to the most extreme of 18 (more serious disease).

Time frame:
Baseline to Week 16
Reported as:
Least squares mean · Percentage of change
Percent Change in Modified Total Lesion Sign Score (mTLSS) for Hand/Foot Lesions From Baseline to Week 16
Percentage of changeMatching PlaceboDupilumab Q2W
Percent Change in Modified Total Lesion Sign Score (mTLSS) for Hand/Foot Lesions From Baseline to Week 16-31.0 (-42.6 to -19.4)-69.4 (-80.9 to -58.0)
SecondaryChange From Baseline to Week 16 in Weekly Average of Daily Hand and Foot Peak Pain NRS

Pain NRS Scale is an assessment tool used to report the intensity of a participant's pain. Participants will select the number between 0 and 10 that fits best to their worst pain intensity over the past 24 hours (0 = no pain and 10 = the worst pain possible).

Time frame:
Baseline to week 16
Reported as:
Least squares mean · Score on a scale
Change From Baseline to Week 16 in Weekly Average of Daily Hand and Foot Peak Pain NRS
Score on a scaleMatching PlaceboDupilumab Q2W
Change From Baseline to Week 16 in Weekly Average of Daily Hand and Foot Peak Pain NRS-1.93 ± 0.432-4.66 ± 0.426
SecondaryMean Change From Baseline to Week 16 in Weekly Average of Daily Sleep NRS

Sleep NRS is an 11-point scale (0 to 10) in which 0 indicates worst possible sleep while 10 indicates best possible sleep.

Time frame:
Baseline to week 16
Reported as:
Least squares mean · Score on a scale
Mean Change From Baseline to Week 16 in Weekly Average of Daily Sleep NRS
Score on a scaleMatching PlaceboDupilumab Q2W
Mean Change From Baseline to Week 16 in Weekly Average of Daily Sleep NRS-0.00 ± 0.3350.88 ± 0.334
SecondaryChange From Baseline to Week 16 in Percent Surface Area of Hand and Foot Involvement With Atopic Dermatitis (AD)
Time frame:
Baseline to week 16
Reported as:
Least squares mean · Percentage of hand and foot BSA
Change From Baseline to Week 16 in Percent Surface Area of Hand and Foot Involvement With Atopic Dermatitis (AD)
Percentage of hand and foot BSAMatching PlaceboDupilumab Q2W
Change From Baseline to Week 16 in Percent Surface Area of Hand and Foot Involvement With Atopic Dermatitis (AD)-10.01 ± 2.388-16.70 ± 2.375
SecondaryPercent Change From Baseline to Week 4 in Weekly Average of Daily Hand and Foot Peak Pruritus NRS

Pruritus NRS is an assessment tool that is used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period; maximum itch intensity on a scale of 0 - 10 (0 = no itch; 10 = worst itch imaginable).

Time frame:
Baseline to week 4
Reported as:
Least squares mean · Percentage of change
Percent Change From Baseline to Week 4 in Weekly Average of Daily Hand and Foot Peak Pruritus NRS
Percentage of changeMatching PlaceboDupilumab Q2W
Percent Change From Baseline to Week 4 in Weekly Average of Daily Hand and Foot Peak Pruritus NRS-25.6 (-36.3 to -15.0)-47.2 (-57.7 to -36.6)
SecondaryPercentage of Participants With Improvement (Reduction) of Weekly Average of Daily Hand and Foot Peak Pruritus NRS ≥4 From Baseline to Week 4

Pruritus NRS is an assessment tool that is used to report the intensity of a participant's pruritus (itch), both maximum and average intensity, during a 24-hour recall period; maximum itch intensity on a scale of 0 - 10 (0 = no itch; 10 = worst itch imaginable).

Time frame:
Baseline to week 4
Reported as:
Number · Percentage of participants
Percentage of Participants With Improvement (Reduction) of Weekly Average of Daily Hand and Foot Peak Pruritus NRS ≥4 From Baseline to Week 4
Percentage of participantsMatching PlaceboDupilumab Q2W
Percentage of Participants With Improvement (Reduction) of Weekly Average of Daily Hand and Foot Peak Pruritus NRS ≥4 From Baseline to Week 49.134.3
SecondaryPercent Change From Baseline to Week 16 in Hand Eczema Severity Index (HECSI) Score in Participants With Hand Dermatitis

For participants with hand dermatitis HECSI is an instrument used in clinical trials to rate the severity of 6 clinical signs of hand eczema and the extent of the lesions on each of 5 hand areas by use of standard scales. The total HECSI score is based on a 4-point severity scale ranging from 0 (none/absent) to 3 (severe) and a 5-point scale rating the affected area(s) ranging from 0 (0% affected area) to 4 (76% to 100% affected area). The range for the combined HECSI score is from 0 to 360 (5x6x3x4).

Time frame:
Baseline to week 16
Reported as:
Mean · Percentage of change
Percent Change From Baseline to Week 16 in Hand Eczema Severity Index (HECSI) Score in Participants With Hand Dermatitis
Percentage of changeMatching PlaceboDupilumab Q2W
Percent Change From Baseline to Week 16 in Hand Eczema Severity Index (HECSI) Score in Participants With Hand Dermatitis-33.8 ± 42.21-68.2 ± 25.56
SecondaryPercentage of Participants With HECSI-75 at Week 16

HECSI-75 is defined as HECSI score has ≥75% improvement from baseline for participants with hand dermatitis.

Time frame:
At week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With HECSI-75 at Week 16
Percentage of participantsMatching PlaceboDupilumab Q2W
Percentage of Participants With HECSI-75 at Week 1621.546.9
SecondaryPercentage of Participants With HECSI-50 at Week 16

HECSI-50 is defined as HECSI score has ≥50% improvement from baseline, for participants with hand dermatitis.

Time frame:
At week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With HECSI-50 at Week 16
Percentage of participantsMatching PlaceboDupilumab Q2W
Percentage of Participants With HECSI-50 at Week 1630.875.0
SecondaryPercentage of Participants With HECSI-90 at Week 16

HECSI-90 is defined as HECSI score has ≥90% improvement from baseline for participants with hand dermatitis.

Time frame:
At week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With HECSI-90 at Week 16
Percentage of participantsMatching PlaceboDupilumab Q2W
Percentage of Participants With HECSI-90 at Week 169.218.8
SecondaryChange From Baseline to Week 16 in Quality of Life in Hand Eczema Questionnaire (QOLHEQ)

For participants with hand dermatitis, QOLHEQ is an instrument to assess disease specific Health Related Quality of Life (HRQOL) in those suffering from hand eczema. QOLHEQ overall scoring ranges as follows: 0 (best score) to 117 (worst score).

Time frame:
Baseline to week 16
Reported as:
Mean · Score on a scale
Change From Baseline to Week 16 in Quality of Life in Hand Eczema Questionnaire (QOLHEQ)
Score on a scaleMatching PlaceboDupilumab Q2W
Change From Baseline to Week 16 in Quality of Life in Hand Eczema Questionnaire (QOLHEQ)-13.36 ± 21.222-38.70 ± 23.920
SecondaryMean Change From Baseline to Week 16 in Work Productivity and Impairment (WPAI) and Classroom Impairment Questionnaire (CIQ)

WPAI + CIQ is a self-administered instrument used to capture the impairment to work productivity/classroom impairment and activity due to atopic hand and foot dermatitis. The WPAI+CIQ yields 4 types of scores: absenteeism, presenteeism, work/classroom productivity loss and activity impairment. All scores range from 0 to 100% with 100% indicating total work/classroom productivity impairment and 0 no impairment at all.

Time frame:
Baseline to week 16
Reported as:
Least squares mean · Score on a scale
Mean Change From Baseline to Week 16 in Work Productivity and Impairment (WPAI) and Classroom Impairment Questionnaire (CIQ)
Score on a scaleMatching PlaceboDupilumab Q2W
Mean Change From Baseline to Week 16 in Work Productivity and Impairment (WPAI) and Classroom Impairment Questionnaire (CIQ)-21.26 ± 3.761-36.39 ± 3.649
SecondaryPercentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Through Week 16
Time frame:
Through week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Through Week 16
Percentage of participantsMatching PlaceboDupilumab Q2W
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) Through Week 1674.265.7
SecondaryTrough Concentration of Functional Dupilumab in Serum at Various Time Points
Time frame:
Up to week 28
Reported as:
Mean · Milligrams per Liter (mg/L)
Trough Concentration of Functional Dupilumab in Serum at Various Time Points
Milligrams per Liter (mg/L)Dupilumab 300 mg - Adult ParticipantsDupilumab 200 mg - Adolescent ParticipantsDupilumab 300 mg - Adolescent Participants
Week 00 ± 00 ± 00 ± 0
Week 1651.2 ± 22.034.0 ± 10.737.1 ± 15.9
Week 287.37 ± 25.060.0 ± 84.97.54 ± 16.9
SecondaryNumber of Participants With Treatment-Emergent (TE) Anti-Drug Antibody (ADA)
Time frame:
Up to week 28
Reported as:
Number · Participants
Number of Participants With Treatment-Emergent (TE) Anti-Drug Antibody (ADA)
ParticipantsMatching PlaceboDupilumab Q2W
Treatment-Boosted Response00
Treatment-Emergent Response18
SecondaryNumber of Participants With Treatment-Emergent ADA by Maximum Titer Category
Time frame:
Up to Week 28
Reported as:
Number · Participants
Number of Participants With Treatment-Emergent ADA by Maximum Titer Category
ParticipantsMatching PlaceboDupilumab Q2W
Low (<1,000)18
Moderate (1,000 to 10,000)00
High (>10,000)00

Adverse events

Collected over From first dose to Week 28. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Matching Placebo0/66 (0%)1/66 (1.5%)34/66 (51.5%)
Dupilumab Q2W0/67 (0%)3/67 (4.5%)33/67 (49.3%)
Most frequent serious events
Most frequent serious events
EventMatching PlaceboDupilumab Q2W
AppendicitisInfections and infestations1/660/67
Post procedural infectionInfections and infestations0/661/67
Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/661/67
Metastases to lungNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/661/67
DizzinessNervous system disorders0/661/67
SyncopeNervous system disorders0/661/67
Most frequent other events
Most frequent other events
EventMatching PlaceboDupilumab Q2W
Dermatitis atopicSkin and subcutaneous tissue disorders16/666/67
NasopharyngitisInfections and infestations8/6616/67
COVID-19Infections and infestations14/6611/67
Upper respiratory tract infectionInfections and infestations3/667/67
Blood creatine phosphokinase increasedInvestigations1/664/67

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Matching PlaceboDupilumab Q2WTotal
Mean33.4 ± 14.6635.8 ± 17.0734.6 ± 15.9
Sex: Female, Male
Sex: Female, Male(Participants)Matching PlaceboDupilumab Q2WTotal
Female384583
Male282250
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Matching PlaceboDupilumab Q2WTotal
Hispanic or Latino235
Not Hispanic or Latino6364127
Unknown or Not Reported101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Matching PlaceboDupilumab Q2WTotal
White5353106
Black or African American437
Asian8917
American Indian or Alaska Native011
Other112
08

Study locations

48 sites
  • Regeneron Study Site
    Birmingham, Alabama 35209, United States
  • Regeneron Study Site
    Redwood City, California 94063, United States
  • Regeneron Study Site
    Washington, District of Columbia 20037, United States
  • Regeneron Study Site
    Macon, Georgia 31217, United States
  • Regeneron Study Site
    Sandy Springs, Georgia 30328, United States
  • Regeneron Study Site
    Columbus, Indiana 47201, United States
  • Regeneron Study Site
    Rockville, Maryland 20850, United States
  • Regeneron Study Site
    Saint Joseph, Missouri 64506, United States
  • Regeneron Study Site
    Saint Louis, Missouri 63104, United States
  • Regeneron Study Site
    Kew Gardens, New York 11415, United States
  • Regeneron Study Site
    Mineola, New York 11501, United States
  • Regeneron Study Site
    Winston-Salem, North Carolina 27157, United States
  • Regeneron Study Site
    Portland, Oregon 97239, United States
  • Regeneron Study Site
    Houston, Texas 77004, United States
  • Regeneron Study Site
    Norfolk, Virginia 23502, United States
  • Regeneron Study Site
    Morgantown, West Virginia 26505, United States
  • Regeneron Study Site
    Milwaukee, Wisconsin 53226, United States
  • Regeneron Study Site
    Langenau, Baden Wurttemberg 89129, Germany
  • Regeneron Study Site
    Frankfurt, Hessen 60590, Germany
  • Regeneron Study Site
    Augsburg, 86179, Germany
  • Regeneron Study Site
    Berlin, 10117, Germany
  • Regeneron Study Site
    Berlin, 10789, Germany
  • Regeneron Study Site
    Bonn, 53127, Germany
  • Regeneron Study Site
    Dresden, 01307, Germany
  • Regeneron Study Site
    Gera, 07548, Germany
  • Regeneron Study Site
    Kiel, 24105, Germany
  • Regeneron Study Site
    Luebeck, 23538, Germany
  • Regeneron Study Site
    Mahlow, 15831, Germany
  • Regeneron Study Site
    Muenster, 48149, Germany
  • Regeneron Study Site
    Kawasaki, Kanagawa 211-0063, Japan
  • Regeneron Study Site
    Sakai, Osaka 593-8324, Japan
  • Regeneron Study Site
    Shinjuku, Tokyo 169-0075, Japan
  • Regeneron Study Site
    Tachikawa, Tokyo 190-0023, Japan
  • Regeneron Study Site
    Kyoto, 602-8566, Japan
  • Regeneron Study Site
    Osaka, 532-0003, Japan
  • Regeneron Study Site
    Tokyo, 105-0012, Japan
  • Regeneron Study Site
    Tokyo, 143-0023, Japan
  • Regeneron Study Site
    Bialystok, 15-453, Poland
  • Regeneron Study Site
    Chorzow, 41-516, Poland
  • Regeneron Study Site
    Katowice, 40-648, Poland
  • Regeneron Study Site
    Katowice, 40-851, Poland
  • Regeneron Study Site
    Kielce, 25-155, Poland
  • Regeneron Study Site
    Ostrowiec Swietokrzyski, 27-400, Poland
  • Regeneron Study Site
    Warszawa, 01-142, Poland
  • Regeneron Study Site
    Warszawa, 02-692, Poland
  • Regeneron Study Site
    Warszawa, 02-953, Poland
  • Regeneron Study Site
    Wroclaw, 50-381, Poland
  • Regeneron Study Site
    Wroclaw, 51-318, Poland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.

Access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Aug 2022, 16 months.

Results were first posted in Dec 2023, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2020
First posted
Jun 5, 2020
StartActual
Apr 14, 2021
Primary completionActual
Aug 31, 2022
CompletionActual
Nov 23, 2022
Results first posted
Dec 22, 2023
Last update
Dec 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04417894
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Jun 5, 2020
Start date
Apr 14, 2021
Primary completion
Aug 31, 2022
Completion
Nov 23, 2022
Results posted
Dec 22, 2023
Last update
Dec 22, 2023

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion